| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SERA | Class A Common Stock | Sale | -$14 | -2 | -25% | $7.18 | 6 | Jan 10, 2025 | Held by Catalyst Health Ventures Follow-on Fund, L.P. | F1, F2, F6 |
| transaction | SERA | Class A Common Stock | Sale | -$8 | -1 | -16.67% | $8.03 | 5 | Jan 10, 2025 | Held by Catalyst Health Ventures Follow-on Fund, L.P. | F1, F3, F6 |
| transaction | SERA | Class A Common Stock | Sale | -$19 | -3 | -60% | $6.39 | 2 | Jan 13, 2025 | Held by Catalyst Health Ventures Follow-on Fund, L.P. | F1, F4, F6 |
| transaction | SERA | Class A Common Stock | Sale | -$13 | -2 | -100% | $6.29 | 0 | Jan 14, 2025 | Held by Catalyst Health Ventures Follow-on Fund, L.P. | F1, F5, F6 |
| transaction | SERA | Class A Common Stock | Sale | -$35.2K | -4.9K | -27.69% | $7.18 | 12.8K | Jan 10, 2025 | Held by CHV Investments, LLC | F1, F2, F6 |
| transaction | SERA | Class A Common Stock | Sale | -$13.4K | -1.67K | -13.09% | $8.03 | 11.1K | Jan 10, 2025 | Held by CHV Investments, LLC | F1, F3, F6 |
| transaction | SERA | Class A Common Stock | Sale | -$40.2K | -6.29K | -56.57% | $6.39 | 4.83K | Jan 13, 2025 | Held by CHV Investments, LLC | F1, F4, F6 |
| transaction | SERA | Class A Common Stock | Sale | -$30.4K | -4.83K | -100% | $6.29 | 0 | Jan 14, 2025 | Held by CHV Investments, LLC | F1, F5, F6 |
| transaction | SERA | Class A Common Stock | Sale | -$13.5K | -1.88K | -27.85% | $7.18 | 4.87K | Jan 10, 2025 | Held by Catalyst Health Ventures, L.P. | F1, F2, F6 |
| transaction | SERA | Class A Common Stock | Sale | -$5.16K | -643 | -13.2% | $8.03 | 4.23K | Jan 10, 2025 | Held by Catalyst Health Ventures, L.P. | F1, F3, F6 |
| transaction | SERA | Class A Common Stock | Sale | -$15.4K | -2.42K | -57.11% | $6.39 | 1.81K | Jan 13, 2025 | Held by Catalyst Health Ventures, L.P. | F1, F4, F6 |
| transaction | SERA | Class A Common Stock | Sale | -$11.4K | -1.81K | -100% | $6.29 | 0 | Jan 14, 2025 | Held by Catalyst Health Ventures, L.P. | F1, F5, F6 |
| transaction | SERA | Class A Common Stock | Sale | -$19.3K | -2.69K | -27.57% | $7.18 | 7.07K | Jan 10, 2025 | Held by Catalyst Health Ventures (PF), L.P. | F1, F2, F6 |
| transaction | SERA | Class A Common Stock | Sale | -$7.4K | -921 | -13.02% | $8.03 | 6.15K | Jan 10, 2025 | Held by Catalyst Health Ventures (PF), L.P. | F1, F3, F6 |
| transaction | SERA | Class A Common Stock | Sale | -$22.1K | -3.46K | -56.2% | $6.39 | 2.7K | Jan 13, 2025 | Held by Catalyst Health Ventures (PF), L.P. | F1, F4, F6 |
| transaction | SERA | Class A Common Stock | Sale | -$17K | -2.7K | -100% | $6.29 | 0 | Jan 14, 2025 | Held by Catalyst Health Ventures (PF), L.P. | F1, F5, F6 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The transaction(s) reported on this Form 4 was/were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2024. |
| F2 | The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $7.00 to $7.37, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade. |
| F3 | The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $8.00 to $8.07, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade. |
| F4 | The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $6.13 to $6.75, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade. |
| F5 | The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $6.03 to $6.57, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade. |
| F6 | CHV GP LLC is the general partner of CHV LP and Catalyst Health Ventures (PF), L.P. ("CHV PF"). CHV I GP LLC (formerly known as "CHV III GP LLC") is the general partner of CHV Investments LLC ("CHV Investments") and Catalyst Health Ventures Follow-on Fund, L.P. ("CHV FO", together with CHV LP, CHV PF and CHV Investments, the "CHV Funds"). Joshua Phillips, a member of the Issuer's board of directors, is a managing member of CHV GP LLC and CHV I GP LLC, and a limited partner of CHV PF, CHV Investments, CHV GP LLC, and CHV I GP LLC. The securities held by the CHV Funds may be deemed to be beneficially owned by Joshua Phillips. Joshua Phillips disclaims beneficial ownership of these securities except to the extent of his pecuniary benefit therein. |